Eisai Co. Ltd. wants a transitional arrangement to give patients in the UK suffering from advanced thyroid cancer access to its tyrosine kinase inhibitor Lenvima (lenvatinib), which is caught in a market access maze there - despite having EU marketing authorization - because it was not appraised before the controversial Cancer Drugs Fund closed last year.
"Lenvatinib was approved by the European Commission in May 2015, by which time the CDF had closed," Gary Hendler, chairman...





